A Phase I, Open Label Study to Evaluate the Safety, Tolerability and Immunogenicity of PENNVAX-B (Gag, Pol, Env) + Electroporation in HIV-1 Infected Adult Participants.
Phase of Trial: Phase I
Latest Information Update: 06 Jan 2015
At a glance
- Drugs HIV clade B DNA vaccine Inovio (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacodynamics
- 10 Jun 2017 Biomarkers information updated
- 06 Jan 2015 Results published in an Inovio Pharmaceuticals media release and in the journal Molecular Therapy.
- 13 Mar 2012 Interim results published in an Inovio Pharmaceuticals media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History